Piramal Pharma Limited (PPLPHARMA)
Press Release
Press Release - Q1FY27
- Revenue 2,270 Cr +17% y-y; EBITDA 285 Cr (margin 12.5%, +400 bps y-y); PAT (69) Cr after exceptional item
- All three businesses delivered mid-to-high teens revenue growth with EBITDA margin expansion
- CDMO: 19% revenue growth, broad-based across India and overseas, improved commercial team, strong execution
- CHG: Maintained US leadership in inhalation anesthesia, Kenalog supplies to start Q2FY27
- PCH: 15% growth driven by power brands (23%) and e-commerce (40%), premiumization and brand investments
- EBITDA margin expansion driven by higher utilization, pricing discipline, and operational excellence
- Sellersville US facility passed US FDA inspection, maintaining zero OAI status
- Management expects sustained revenue growth and EBITDA expansion through FY27
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PPLPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PPLPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Piramal Pharma Limited
Important.
The summary above is generated automatically from Piramal Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.